Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy

Rejinold, N. Sanoj; Piao, Huiyan; Jin, Geun‐woo; Choi, Gun

doi:10.1016/j.colsurfb.2021.112063

Cited by 8 publications

(3 citation statements)

References 69 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identical absorption bands were also obtained from the as-made NIC-MgO-HPMC, which demonstrated the formation of broken π-π stacking interactions [38]. The greatest challenge in NIC delivery is its low aqueous solubility as previously reported by many researchers, including our group by repurposing technology using polymers [39,40] as well as inorganic clays [41].…”

Section: Resultssupporting

confidence: 65%

See 1 more Smart Citation

Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection

Jin¹,

Choi

Piao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic is a serious global health threat mainly due to the surging cases along with new variants of COVID-19. Though global vaccinations have indeed some effects on the virus spread, its longevity is still unknown. Therefore an orally administrable anti-viral agent against SARS-CoV-2 would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we repurposed niclosamide (NIC), an FDA approved anthelmintic drug in to MgO, which was further coated with hydroxyl propyl methyl cellulose (HPMC) to get the de-sired product called NIC-MgO-HPMC, which has improved anti-SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of NIC-MgO-HPMC on SARS-CoV-2 replication leads to the prevention of inflammation as well as lung injury. These data strongly support that repurposed NIC-MgO-HPMC could be highly beneficial for controlling the ongoing pandemic thereby achieving an endemic phase.

show abstract

Section: Resultssupporting

confidence: 65%

“…The greatest challenge in NIC delivery is its low aqueous solubility as previously reported by many researchers, including our group by repurposing technology using polymers [39, 40] as well as inorganic clays [41].…”

Section: Resultsmentioning

confidence: 99%

Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection

Jin¹,

Choi

Piao

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Newly, it has been identified that reusing already available medications could be a good method to formulate an efficient drug for SARS-CoV-2 infection. Though there are many FDA-accepted medications, it has been shown that the anthelmintic medication niclosamide (NIC) has remarkably great capability versus COVID-19 [ 132 ]. Sanoj Rejinold et al used a simple self-assembling method in which Zein NPs were effectively utilized to load NICs.…”

Section: Nanoparticles As a Great Blessingmentioning

confidence: 99%

Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview

Gholizadeh

Yasamineh

Amini

et al. 2022

Virol J

View full text Add to dashboard Cite

In December 2019, Coronavirus Disease 2019 (COVID-19) was reported in Wuhan, China. Comprehensive strategies for quick identification, prevention, control, and remedy of COVID-19 have been implemented until today. Advances in various nanoparticle-based technologies, including organic and inorganic nanoparticles, have created new perspectives in this field. These materials were extensively used to control COVID-19 because of their specific attribution to preparing antiviral face masks, various safety sensors, etc. In this review, the most current nanoparticle-based technologies, applications, and achievements against the coronavirus were summarized and highlighted. This paper also offers nanoparticle preventive, diagnostic, and treatment options to combat this pandemic. Graphical Abstract

show abstract

The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2

Choi,

Rejinold,

Piao

et al. 2023

Small

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID‐19) pandemic is a serious global threat with surging new variants of concern. Although global vaccinations have slowed the pandemic, their longevity is still unknown. Therefore, new orally administrable antiviral agents are highly demanded. Among various repurposed drugs, niclosamide (NIC) is the most potential one for various viral diseases such as COVID‐19, SARS (severe acute respiratory syndrome), MERS (middle east respiratory syndrome), influenza, RSV (respiratory syncytial virus), etc. Since NIC cannot be effectively absorbed, a required plasma concentration for antiviral potency is hard to maintain, thereby restricting its entry into the infected cells. Such a 60‐year‐old bioavailability challenging issue has been overcome by engineering with MgO and hydroxypropyl methylcellulose (HPMC), forming hydrophilic NIC–MgO–HPMC, with improved intestinal permeability without altering NIC metabolism as confirmed by parallel artificial membrane permeability assay. The inhibitory effect on SARS‐CoV‐2 replication is confirmed in the Syrian hamster model to reduce lung injury. Clinical studies reveal that the bioavailability of NIC hybrid drug can go 4 times higher than the intact NIC. The phase II clinical trial shows a dose‐dependent bioavailability of NIC from hybrid drug suggesting its potential applicability as a game changer in achieving the much‐anticipated endemic phase.

show abstract

Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy

Abstract: Graphical abstract

Cited by 8 publications

References 69 publications

Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection

Orally administered niclosamide-based organic/inorganic hybrid suppresses SARS-CoV-2 infection

Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview

The Next Generation COVID‐19 Antiviral; Niclosamide‐Based Inorganic Nanohybrid System Kills SARS‐CoV‐2

Contact Info

Product

Resources

About